Acute Lymphoblastic Leukemia With Failed Remission Clinical Trial
Official title:
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of Differentiation Antigen 19 (CD19) has been proved as a potent approach to attain remission in B-cell R/R patients. Therefore, the investigators conduct a trial to evaluate the the efficacy and safety of locally producing CAR T cells targeting CD19, and to analyze the outcome of enrolled B-cell ALL patients with active disease or persistent residual disease.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Diagnosed as CD19+ B-cell acute lymphoblastic leukemia; - Fail to achieve remission, or with persistent residual disease after at least 2 cycles of consolidation; - With an estimated survival of higher than 3 months (according to investigator's judgement); - Sufficient organ function: left ventricular ejection fractions= 0.5 by echocardiography, creatinine < 1.6 mg/dL, aspartate aminotransferase/aspartate aminotransferase < 3 x upper limit of normal, bilirubin <2.0 mg/dL; - Karnofsky performance status = 60 or ECOG = 2. Exclusion Criteria: - Intolerant to immunosuppressive chemotherapies; - With active infection or other uncontrolled complications; - With history of seizure; - Active hepatitis B or hepatitis C infection and HIV infection; - Pregnant or lactating women, or patients refusing to take effective contraception measures; - Other contraindications that considered inappropriate to participate in this trial (according to investigator's judgement). |
Country | Name | City | State |
---|---|---|---|
China | The Fisrt Affiliated Hospital of Soochow University | Suzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Soochow University | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
China,
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Blood. 2016 Sep 15;128(11):1533. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete remission | defined as less than 5% blasts in the bone marrow without myelosuppression, no circulating blasts in peripheral blood, and the absence of extramedullary disease, regardless of cell count recovery | 1 month post infusion | |
Primary | Minimal residual disease response | defined as less than 0.01% bone marrow blasts assessed by multiparameter flow cytometry, and absence of genetic aberrants assessed by karyotype analysis or molecular detection | 1 month post infusion | |
Primary | Cytokine release syndrome | grading according to the criteria proposed by Lee, et al (Blood, 2014, 124: 188-195). This grading system ranges from grade 1 (best) to grade 5 (worst), by measuring related symptoms (such as fever, nausea, fatigue, headache, etc.), oxygen requirement, blood pressure and organ toxicity (referred to CTCAE v4.0 grading) | 1 month post infusion | |
Secondary | Overall survival | calculating from the day of CAR T-cell infusion to death or the end of follow-up | 1 year post infusion | |
Secondary | Leukemia-free survival | calculating from the day of CAR T-cell infusion to death, disease progression or the end of follow-up | 1 year post infusion | |
Secondary | Cumulative incidence of relapse | calculating from the day of CAR T-cell infusion to disease progression or the end of follow-up | 1 year post infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05809284 -
Determining the Mechanisms of Loss of CAR T Cell Persistence
|
||
Recruiting |
NCT04049383 -
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
|
Phase 1 | |
Recruiting |
NCT06445803 -
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
|
Phase 1 | |
Recruiting |
NCT05292664 -
Venetoclax Basket Trial for High Risk Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT03751072 -
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)
|
||
Not yet recruiting |
NCT05779930 -
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
|
Early Phase 1 | |
Terminated |
NCT03515200 -
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT06034561 -
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
|
Phase 2 |